With over a million UK patients now on oral anticoagulants, the requirement for rapid warfarin reversal therapy is becoming increasingly necessary. Here, transfusion scientist Barry Hill talks to a leading industry specialist about the latest developments.
(Image: National Cancer Institute)
In his role as medical adviser at Octapharma, Andrew Law is responsible for medical information, clinical trial support and drug safety for the company’s UK product portfolio. Andrew graduated from medical school in Bristol and then completed his general practice training before joining Octapharma as medical adviser.
Founded by Wolfgang Marguerre in 1983, Octapharma is the world’s largest privately owned human plasma fractionation manufacturer, as Andrew explains: “Octapharma’s core mission is the development and production of effective medicines derived from human proteins in the clinical therapeutic areas of haematology, immunotherapy and intensive care and emergency medicine. As a pharmaceutical company, we have been bringing innovative products to the UK market since 1993.
“Octapharma was the first company to bring pathogen-reduced solvent detergent fresh frozen plasma (OctaplasLG) to the UK, as well as the first UK-licensed four-factor prothrombin complex concentrate (PCC) Octaplex. We are essentially a patient-oriented organisation with a workforce that understands patient needs. Our entrepreneurial spirit is spurred by a thirst for collaboration and knowledge to improve patients’ lives.”
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.